NCT04615156View on ClinicalTrials.gov

18F-2-fluoro-2-deoxy-D-glucose in Positron Emission Tomography Computed Tomography

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

10,000

Participants

Timeline

Start Date

November 1, 2020

Primary Completion Date

November 1, 2027

Study Completion Date

November 1, 2027

Conditions
Solitary Pulmonary NoduleOncology18F-2-fluoro-2-deoxy-D-glucoseAdverse Event
Interventions
DRUG

18F-2-fluoro-2-deoxy-D-glucose

Administration of 18F-2-fluoro-2-deoxy-D-glucose for the purposes of diagnosis.

All Listed Sponsors
lead

Eastern Health, Canada

OTHER